217 related articles for article (PubMed ID: 26981724)
1. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
ACS Appl Mater Interfaces; 2024 Jun; 16(23):29686-29698. PubMed ID: 38813771
[TBL] [Abstract][Full Text] [Related]
4. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
[TBL] [Abstract][Full Text] [Related]
5. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Chitkara D; Mittal A; Behrman SW; Kumar N; Mahato RI
Bioconjug Chem; 2013 Jul; 24(7):1161-73. PubMed ID: 23758084
[TBL] [Abstract][Full Text] [Related]
6. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
7. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
8. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
Mittal A; Chitkara D; Behrman SW; Mahato RI
Biomaterials; 2014 Aug; 35(25):7077-87. PubMed ID: 24836307
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
11. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
14. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
15. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
Zhao M; Tominaga Y; Ohuchida K; Mizumoto K; Cui L; Kozono S; Fujita H; Maeyama R; Toma H; Tanaka M
Cancer Sci; 2012 Jan; 103(1):58-66. PubMed ID: 21954965
[TBL] [Abstract][Full Text] [Related]
16. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
18. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]